Scarica l'app Stockscreener
0.9251
1.05%
-0.0098
Precedente Chiudi:
$0.9349
Aprire:
$0.94
Volume 24 ore:
34,100
Relative Volume:
0.38
Capitalizzazione di mercato:
$5.84M
Reddito:
-
Utile/perdita netta:
$-14.29M
Rapporto P/E:
-0.2319
EPS:
-3.99
Flusso di cassa netto:
$-12.27M
1 W Prestazione:
-11.05%
1M Prestazione:
-23.55%
6M Prestazione:
-49.73%
1 anno Prestazione:
-71.05%
Intervallo 1D:
$0.9203
$0.9676
Intervallo di 1 settimana:
$0.90
$1.04
Portata 52W:
$0.90
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Confronta APRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.9251 | 5.90M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com Nigeria
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com Nigeria
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com
Aprea Therapeutics raises $3.1 million in private placement - Investing.com
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan
Why Aprea Therapeutics Inc. stock is seen as undervaluedMarket Weekly Review & Growth Focused Investment Plans - Newser
Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st
How Aprea Therapeutics Inc. stock performs in rising dollar environmentJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Head and Neck Cancer Therapeutics Market | Global Market Analysis Report2035 - Fact.MR
Why Aprea Therapeutics Inc. stock could rally in 20252025 Top Decliners & Stepwise Swing Trade Plans - moha.gov.vn
Is Aprea Therapeutics Inc a good long term investmentRSI Overbought/Oversold & Learn From the Strategies of Institutions - earlytimes.in
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Why Aprea Therapeutics Inc. stock could outperform in 2025July 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Aprea Therapeutics Inc. stock sustain free cash flow growthWatch List & Weekly Momentum Picks - newser.com
How supply chain issues affect Aprea Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Aprea Therapeutics Inc. stock a top momentum play2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Tools to assess Aprea Therapeutics Inc.’s risk profileQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocks2025 Valuation Update & Weekly High Return Opportunities - newser.com
Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target - Barchart.com
Is Aprea Therapeutics Inc. stock attractive after correction2025 Big Picture & Fast Gaining Stock Reports - newser.com
Is Aprea Therapeutics Inc. stock poised for growthJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):